局部晚期胰腺癌的放射治疗

doi:10.3760/cma.j.issn.1673-422X.2015.01.017

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (1): 64-66.doi: 10.3760/cma.j.issn.1673-422X.2015.01.017

局部晚期胰腺癌的放射治疗

金琳芝, 王仁本

250117济南大学山东省医学科学院医学与生命科学学院（金琳芝）；山东省肿瘤医院放疗一科山东省放射肿瘤学重点实验室（金琳芝、王仁本）

收稿日期:2014-06-18 修回日期:2014-08-04 出版日期:2015-01-08 发布日期:2015-01-07
通讯作者: 王仁本 E-mail:wangrenben@sina.cn

Radiotherapy of locally advanced pancreatic cancer

Jin Linzhi, Wang Renben

School of Medicine and Life Sciences, University of Ji’nan-Shandong Academy of Medical Sciences; First Department of Radiation Oncology, Shandong Cancer Hospital, Key Laboratory of Radiation Oncology of Shandong Province, Ji’nan 250117, China

Received:2014-06-18 Revised:2014-08-04 Online:2015-01-08 Published:2015-01-07
Contact: Wang Renben E-mail:wangrenben@sina.cn

摘要/Abstract

摘要： 过去局部晚期胰腺癌主要的非手术治疗方式是化疗，放疗在治疗局部晚期胰腺癌中的作用存在争议。随着精确放疗技术的发展，放疗已逐渐成为局部晚期胰腺癌的主要治疗手段之一。另外，近距离放射性粒子植入技术为局部晚期胰腺的治疗提供了新的路径。但放疗的最佳照射技术、放疗剂量、同步化疗的药物仍无确切标准，有待进一步临床研究。

关键词: 胰腺肿瘤, 放射疗法

Abstract: Over the past years, the nonsurgical treatment of locally advanced pancreatic cancer was chemotherapy， whereas the role of radiotherapy was controversial. With the development of precise radiotherapy techniques, radiotherapy has become one of the main treatments. In addition, brachytherapy radioactive seed implantation provides a new treatment method for locally advanced pancreatic cancer. However, there are no criteria about the optimum technology, dose and concurrently chemotherapy drugs, which need further clinical research.

Key words: Pancreatic neoplasms, Radiotherapy

金琳芝, 王仁本. 局部晚期胰腺癌的放射治疗[J]. 国际肿瘤学杂志, 2015, 42(1): 64-66.

Jin Linzhi, Wang Renben. Radiotherapy of locally advanced pancreatic cancer[J]. Journal of International Oncology, 2015, 42(1): 64-66.

参考文献

［1］ Brunner TB, ScottBrown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma［J］. Radiat Oncol, 2010, 5: 64. ［2］ Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6 000 rads) radiation alone, moderate dose radiation (4 000 rads + 5fluorouracil), and high dose radiation + 5fluorouracil: the gastrointestinal tumor study group［J］. Cancer, 1981, 48(8): 1705-1710. ［3］ Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase Ⅲ study of radiotherapy alone or with 5fluorouracil and mitomycinC in patients with locally advanced adenocarcinoma of the pancreas: eastern cooperative oncology group study E8282［J］. Int J Radiat Oncol Biol Phys, 2005, 62(5): 1345-1350. ［4］ Wang BH, Cao WM, Yu J, et al. Gemcitabinebased concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer［J］. Asian Pac J Cancer Prev, 2012, 13(5): 2129-2132. ［5］ Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial［J］. J Clin Oncol, 2011, 29(31): 4105-4112. ［6］ Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twiceweekly infusion of gemcitabine and concurrent externalbeam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience［J］. Cancer, 2013, 119(2): 277-284. ［7］ Kim JS, Lim JH, Kim JH, et al. Phase Ⅱ clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer［J］. Cancer Chemother Pharmacol, 2012, 70(3): 381-389. ［8］ Trakul N, Koong AC, Maxim PG, et al. Modern radiation therapy techniques for pancreatic cancer［J］. Gastroenterol Clin North Am, 2012, 41(1): 223-235. ［9］ Abelson JA, Murphy JD, Minn AY, et al. Intensitymodulated radiotherapy for pancreatic adenocarcinoma［J］. Int J Radiat Oncol Biol Phys, 2012, 82(4): e595-601. ［10］ Pipas JM, Zaki BI, McGowan MM, et al. Neoadjuvant cetuximab, twiceweekly gemcitabine, and intensitymodulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma［J］. Ann oncol, 2012, 23(11): 2820-2827. ［11］ Combs SE, Habermehl D, Kessel K, et al. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3Dtreated patient cohort［J］. Strahlenther Onkol, 2013, 189(9): 738-744. ［12］ Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated［J］. Int J Radiat Oncol Biol Phys, 2013, 86(3): 516-522. ［13］ Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration［J］. Ann Surg Oncol, 2010, 17(8): 2092-2101. ［14］ Rwigema JC, Parikh SD, Heron DE, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas［J］. Am J Clin Oncol, 2011, 34(1): 63-69. ［15］ Wang J, Jiang Y, Li J, et al. Intraoperative ultrasoundguided iodine125 seed implantation for unresectable pancreatic carcinoma［J］. J Exp Clin Cancer Res, 2009, 28:88. ［16］ Diaz Beveridge R, Alcolea V, Aparicio J, et al. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice［J］. JOP, 2014,15(1): 19-24. ［17］ Aparicio J, GarcíaMora C, Martín M, et al. A phase Ⅰ, dosefinding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Espaol Multidisciplinario en Cáncer Digestivo (GEMCAD) study［J］. PLoS One, 2014, 9(1): e82209. ［18］ Cetin V, Piperdi B, Bathini V, et al. A phase Ⅱ trial of cetuximab, gemcitabine, 5Fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma［J］. Gastrointest Cancer Res: GCR, 2013, 6 (4 Suppl 1): S2-9. ［19］ Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine［J］. N Engl J Med, 2013, 369(18): 1691-1703.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[6]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[7]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[8]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[9]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[10]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[11]	李进芝, 赵彪, 文晓博, 张明, 袁美芳, 孙梦真, 蒲琴, 杨毅. Monaco系统计算网格尺寸对T₄期鼻咽癌的剂量学影响[J]. 国际肿瘤学杂志, 2023, 50(11): 641-649.
[12]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[13]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇. 重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.
[14]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 新型冠状病毒感染疫情背景下肿瘤患者放射治疗管理相关问题中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(10): 577-584.
[15]	魁国菊, 黄江宾, 张文华, 杨立民. 区域淋巴结大小对胰头腺癌术后复发的影响[J]. 国际肿瘤学杂志, 2023, 50(10): 608-613.

局部晚期胰腺癌的放射治疗

Radiotherapy of locally advanced pancreatic cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价